| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5657195 | Clinical Gastroenterology and Hepatology | 2017 | 31 Pages |
Abstract
In an analysis of data from Phase 2 and Phase 3 trials of eluxadoline (75 or 100 mg) for patients with IBS-D, data revealed no signs of abuse potential for eluxadoline. ClinicalTrials.gov numbers: NCT01130272, NCT01553591, NCT01553747.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Reginald V. Fant, Jack E. Henningfield, Brooks D. Cash, Leonard S. Dove, Paul S. Covington,